We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05334472
Recruitment Status : Recruiting
First Posted : April 19, 2022
Last Update Posted : October 18, 2022
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This is a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.

Condition or disease Intervention/treatment
Multiple Sclerosis Other: Kesimpta

Detailed Description:

The study will aim to enroll ninety-four (94) patients/care partners. The time period for enrollment is dependent on the uptake of KESIMPTA in the real-world.

Data collected for the study will be obtained directly from the patient/care partner within the web-based database: De-identified data will be stored on a secure server and transferred for analysis. Responses from the patient and care partner surveys will be pooled for analysis of study endpoints.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Real World Study to Evaluate Patient and Care Partner Ratings on Early Experience of Injection and Device for KESIMPTA® (Ofatumumab) Indicated for Multiple Sclerosis
Actual Study Start Date : November 24, 2021
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Ofatumumab

Group/Cohort Intervention/treatment
Kesimpta
Patients or caregivers of patients administered Kesimpta
Other: Kesimpta
There is no treatment allocation. Patients administered Kesimpta by prescription that have started before inclusion of the patient into the study will be enrolled.
Other Name: ofatumumab




Primary Outcome Measures :
  1. Proportion of respondents in top two rating categories for device satisfaction on use of KESIMPTA Sensoready [ Time Frame: Up to 6 months, at the time of survey completion ]
    Proportion of respondents (patients and care partners) in top two rating categories (satisfied and extremely satisfied) for device satisfaction on use of KESIMPTA Sensoready®


Secondary Outcome Measures :
  1. Proportion of patients by US region of residence [ Time Frame: Up to 6 months, at the time of survey completion ]
    Census US geographic region of residence (Northeast, Midwest, South, or West)

  2. Proportion of patients by educational level [ Time Frame: Up to 6 months, at the time of survey completion ]
    Proportion of patients by educational level will be collected

  3. Patients Determined Disease Steps (PDDS) [ Time Frame: Up to 6 months, at the time of survey completion ]
    PDDS is used as a proxy to Expanded Disability Status Scale (EDSS). People are asked to choose one out of nine options that best describes how well they walk. 0 is "normal" and 8 is "bedridden."

  4. General QoL [ Time Frame: Up to 6 months, at the time of survey completion ]
    Participants are asked "How is your general health today?" and they have to choose one out of five options that best describes how well they feel from "Poor", "Fair" ,"Good", "Very Good" to "Excellent".

  5. Proportion of patients by Multiple Sclerosis Phenotype [ Time Frame: Up to 6 months, at the time of survey completion ]

    Proportion of patients by Multiple Sclerosis Phenotype is collected:

    • RRMS: Relapsing-Remitting Multiple Sclerosis
    • SPMS: Secondary Progressive Multiple Sclerosis

  6. Proportion of patients with co-morbidities [ Time Frame: Up to 6 months, at the time of survey completion ]
    Proportion of patients with co-morbidities is collected

  7. Importance of healthcare provider (HCP) instructions for first injection [ Time Frame: Up to 6 months, at the time of survey completion ]

    Participants are asked to rate their level of agreement with each statement related to their first Kesimpta injection. 1) I felt it was essential to have a healthcare provider instruct me on how to perform my first KESIMPTA injection using the Sensoready® pen, 2) I felt I needed to have a healthcare provider watch me administer my first KESIMPTA injection using the Sensoready® pen, and 3) I felt comfortable receiving instructions from my healthcare provider in the clinic on how to administer my first KESIMPTA injection using the Sensoready® pen and did not need my healthcare provider to be present to administer it at home.

    Participants are asked to choose five options toward each statement from "Strongly Disagree" to "Strongly Agree".


  8. Proportion of participants with necessity of HCP at first injection [ Time Frame: Up to 6 months, at the time of survey completion ]
    Proportion of participants with necessity of Health Care Professional (HCP) at first injection is collected

  9. Level of anxiety with injections, in general [ Time Frame: Up to 6 months, at the time of survey completion ]
    Participants are asked "Using a scale of 0 to 10, 0 being Not at All Confident and 10 being Extremely Confident, how confident do you feel about your ability to administer KESIMPTA using the Sensoready® pen on your own?"

  10. Proportion of patients performing preparation activities for injection [ Time Frame: Up to 6 months, at the time of survey completion ]

    Proportion of patients performing preparation activities for injection:

    • talk to HCP/family/friends
    • use of oral pain relief medications
    • use of antihistamines prior to injection
    • massage injection site
    • apply ice/cold compress to injection site
    • apply heat/hot compress to injection site
    • apply numbing/pain relieving lotion/cream to injection site
    • perform injection with assistance
    • perform injection under medical supervision
    • other strategies

  11. Proportion of participants by site of administration [ Time Frame: Up to 6 months, at the time of survey completion ]

    Proportion of participants by site of administration is collected:

    • thigh
    • abdomen
    • upper outer arm

  12. Proportion of participants by individual medication as previous Disease Modifying Therapy (DMT) [ Time Frame: Up to 6 months, at the time of survey completion ]
    Proportion of participants by individual medication as previous Disease Modifying Therapy (DMT) is collected among DMT experienced patients

  13. Proportion of participants by reasons to switch from most recent therapy [ Time Frame: Up to 6 months, at the time of survey completion ]
    Proportion of participants by reasons to switch from most recent therapy (insurance, lack of efficacy/wear off effect, side-effects and tolerability, adherence concerns etc.) is collected among DMT experienced patients.

  14. Proportion of patients who are injection naïve or experienced [ Time Frame: Up to 6 months, at the time of survey completion ]
    Proportion pf patients who are injection naïve or experienced (autoinjector or prefilled syringe) is collected.

  15. Proportion of participants by reasons for starting KESIMPTA [ Time Frame: Up to 6 months, at the time of survey completion ]

    Proportion of participants by reasons for starting KESIMPTA is collected:

    • ease of dosing schedule
    • avoidance of infusion clinics
    • at home convenience
    • enhanced efficacy and safety profile
    • HCP recommendation
    • lack of insurance coverage for other DMTs
    • Other

  16. Proportion of patients agreeing with the attributes of the device Usability Characteristics during self-administration [ Time Frame: Up to 6 months, at the time of survey completion ]

    Percentage of patients who agree with each attribute of the device Usability Characteristics during self-administration, based on patient self-report is collected:

    • Overall ease of use
    • Device ergonomics ("feeling" in the hand )
    • Steps for preparing and using device
    • Time required for preparation and use of device
    • Convenience/Flexibility for travel with device

  17. Patient Confidence [ Time Frame: Up to 6 months, at the time of survey completion ]

    Percentage o patients who agree with each attribute regarding confidence, based on patient self-report, is collected:

    • Confidence to self-administer KESIMPTA using the device
    • Intention to continue use of device
    • Recommendation of KESIMPTA device use to others
    • Ease of KESIMPTA's monthly dosing schedule

  18. Overall device satisfaction based on patient self-report and care partner report [ Time Frame: Up to 6 months, at the time of survey completion ]
    Overall device satisfaction based on patient self-report and care partner report is presented. Participants choose between five options from 1: Extremely Dissatisfied, 2 Dissatisfied, 3: Neither Satisfied nor Dissatisfied, 4: Satisfied, 5: Extremely Satisfied. The higher score means a better overall devise satisfaction.

  19. Injection experience based on patient self-report or care partner report [ Time Frame: Up to 6 months, at the time of survey completion ]

    Injection experience based on patient self-report or care partner report is collected. Participants are asked to respond the following statements choosing between five options from 1: Strongly Disagree, 2: Disagree, 3: Neither Agree nor Disagree, 4: Agree, 5: Strongly Agree. The higher score means a better outcome with injection experience.

    • I can use KESIMPTA Sensoready® pen without any interference to my daily routine activities (work, social, or leisure activities)
    • The amount of time required to prepare the KESIMPTA Sensoready® pen for use was reasonable

  20. Time for injection in minutes [ Time Frame: Up to 6 months, at the time of survey completion ]

    Time for injection in minutes, based on patient self-report or care partner report is collected:

    • Time taken for two steps (i.e. removing drug out of refrigerator and injection to disposing pen in sharps container)
    • Total Time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

To ensure a representative sample of patients with MS, the patient study population will include patients who are new to the use of injectable treatments for MS, as well as those with use of other injectable MS treatments prior to initiation of KESIMPTA using the Sensoready® pen.

Patients care partner (formal or informal) may also be eligible for study participation.

Criteria

Patients with MS Inclusion Criteria:

  • Adult aged eighteen (18) years of age or over at the time of the survey
  • Prescribed KESIMPTA within the prior 12 months and currently self-administering treatment using the Sensoready® pen
  • MS diagnosis based on 2017 McDonald criteria

Care Partner Inclusion Criteria:

  • Adult aged eighteen (18) years of age or over
  • Formal or informal care partner of patient with MS prescribed KESIMPTA within the prior 12 months
  • Is currently administering KESIMPTA using the Sensoready® pen on their patient's behalf

Patients with MS Exclusion Criteria:

  • Previously used injection as a part of inclusion in any ofatumumab (OMB) randomized clinical trial
  • Active Hepatitis B virus (HBV)
  • Cognitive impairment that would impact their ability to participate in a survey study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05334472


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals +41613241111 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals

Locations
Layout table for location information
United States, New Jersey
Novartis Investigative Site Recruiting
East Hanover, New Jersey, United States, 07936
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT05334472    
Other Study ID Numbers: COMB157GUS13
First Posted: April 19, 2022    Key Record Dates
Last Update Posted: October 18, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Multiple Sclerosis
MS
NIS
KESIMPTA
ofatumumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Ofatumumab
Antineoplastic Agents